AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Probable ATP-dependent RNA helicase DDX5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P17844

UPID:

DDX5_HUMAN

Alternative names:

DEAD box protein 5; RNA helicase p68

Alternative UPACC:

P17844; B4DLW8; B5BU21; D3DU32; E7ETL9; O75681; Q53Y61

Background:

Probable ATP-dependent RNA helicase DDX5, also known as DEAD box protein 5 and RNA helicase p68, plays a pivotal role in various cellular processes. It is essential for the alternative regulation of pre-mRNA splicing, transcriptional regulation, and skeletal muscle differentiation. DDX5's RNA helicase activity, crucial for tau exon 10 inclusion, is stimulated by single-stranded RNA. It acts as a transcriptional coactivator for androgen receptor AR, p53/TP53, and RUNX2, while repressing transcription in a promoter-specific manner.

Therapeutic significance:

Understanding the role of Probable ATP-dependent RNA helicase DDX5 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.